AR882 for Gout Patients Who Have Not Responded to Prior Uricase Therapy
This open-label Phase 2 study is currently enrolling adults with uncontrolled gout who previously tried a uricase-based treatment (a medication that breaks down uric acid) but did not achieve adequate results. Participants will receive AR882 together with an XOI (xanthine oxidase inhibitor), another uric acid-lowering medication, to evaluate the combination’s safety and effectiveness. Because the […]
Testing Afimetoran for Active Lupus (SLE)
This Phase 2 study is examining whether an investigational drug called afimetoran is safe and effective for adults with active Systemic Lupus Erythematosus (SLE), commonly known as lupus. Participants are randomly assigned to receive either afimetoran or a placebo. Lupus is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissue throughout the […]
Comparing Different Ways of Giving Bimekizumab
This open-label clinical study is currently enrolling adults to evaluate how bimekizumab moves through the body (its pharmacokinetics) and whether it is safe when administered by different routes, such as by injection versus another method. Participants will receive bimekizumab using different methods of administration so researchers can compare how the medication is absorbed, distributed, and […]